Spots Global Cancer Trial Database for epidermal growth factor receptor
Every month we try and update this database with for epidermal growth factor receptor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Blood Detection of EGFR Mutation For Iressa Treatment | NCT02282267 | Lung Adenocarci... | Gefitinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC | NCT01775943 | Lung Neoplasms | - | Ulsan University Hospital | ||
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | NCT04985825 | Cutaneous Squam... | Imgatuzumab | 18 Years - | Centessa Pharmaceuticals plc | |
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | NCT04985825 | Cutaneous Squam... | Imgatuzumab | 18 Years - | Centessa Pharmaceuticals plc | |
| Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer | NCT00973310 | Carcinoma, Non-... | Radiation Thera... | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | NCT01833572 | Non-small-cell ... | Gefitinib | 18 Years - | Fudan University | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | NCT05163249 | Carcinoma, Non-... | Osimertinib Savolitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | NCT00054691 | Skin Cancer | Iressa | 18 Years - | M.D. Anderson Cancer Center | |
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | NCT01774721 | Non-small Cell ... | Dacomitinib (PF... Gefitinib | 18 Years - 99 Years | Pfizer | |
| Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | NCT00739063 | Breast Cancer | Tarceva | - | M.D. Anderson Cancer Center | |
| Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma | NCT00600054 | Recurrent Diffu... | nimotuzumab (an... | 3 Years - 18 Years | YM BioSciences | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma | NCT02370849 | Stomach Neoplas... | nimotuzumab cisplatin S-1 | 18 Years - | ChineseAMS | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | NCT00444678 | Colorectal Canc... Neoplasm Metast... | Cetuximab Oxaliplatin Capecitabine | 18 Years - | NYU Langone Health | |
| Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | NCT01238237 | Glioblastoma Mu... ANAPLASTIC ASTR... GBM Anaplastic Astr... | Superselective ... | 18 Years - | Northwell Health | |
| Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer | NCT00857246 | Gastric Cancer Stomach Cancer | Cetuximab Irinotecan Cisplatin Surgery 5-FU Radiation | 18 Years - | NYU Langone Health | |
| Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | NCT06059690 | Glioblastoma Mu... Glycolytic Inde... Epidermal Growt... | pH Measurement ... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | NCT04676477 | Non-Small Cell ... | HER3-DXd HER3-DXd Osimertinib Osimertinib HER3-DXd HER3-DXd Osimertinib | 18 Years - | Daiichi Sankyo | |
| Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer | NCT04755738 | Advanced Non Sm... | Almonertinib pl... | 18 Years - 80 Years | Qianfoshan Hospital | |
| A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | NCT05940116 | Non-Small Cell ... Solid Tumor | HS-20117 | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | NCT02274337 | Non-Small Cell ... | AC0010 | 18 Years - 70 Years | Sun Yat-sen University | |
| Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma | NCT02370849 | Stomach Neoplas... | nimotuzumab cisplatin S-1 | 18 Years - | ChineseAMS | |
| A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT06417008 | Non-Squamous No... | HS-20117 Aumolertinib | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
| An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment | NCT01074333 | Colorectal Neop... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR | NCT00446225 | Non-Small Cell ... | Erlotinib Carboplatin Gemcitabin Docetaxel Cisplatin | 18 Years - | Spanish Lung Cancer Group | |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | NCT00225758 | Metastatic Brea... | Lapatinib | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | NCT05163249 | Carcinoma, Non-... | Osimertinib Savolitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | NCT01813253 | Gastric Cancer Gastroesophagea... | Irinotecan Nimotuzumab | 20 Years - | Kuhnil Pharmaceutical Co., Ltd. | |
| Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin | NCT01059305 | Skin Cancer | Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of DS-2248 in Participants With Advanced Solid Tumors | NCT01288430 | Solid Tumors Non-small Cell ... | DS-2248 | 18 Years - | Daiichi Sankyo | |
| Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR | NCT00567359 | Non-small Cell ... | Erlotinib | 18 Years - | Massachusetts General Hospital | |
| Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer | NCT00392769 | Endometrial Can... | Cetuximab | - | M.D. Anderson Cancer Center | |
| Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer | NCT00970502 | Cancer of the P... Cancer of the L... Cancer of the N... Paranasal Sinus... Cancer of the H... | erlotinib + cel... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer | NCT01732276 | Breast Cancer | gefitinib | 18 Years - | Jiangmen Central Hospital | |
| Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer | NCT04755738 | Advanced Non Sm... | Almonertinib pl... | 18 Years - 80 Years | Qianfoshan Hospital | |
| Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy | NCT01372189 | Colorectal Canc... Colorectal Aden... | 18 Years - 80 Years | Shandong University | ||
| Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | NCT00034541 | Carcinoma, Non-... | cetuximab paclitaxel carboplatin | 18 Years - | Eli Lilly and Company | |
| TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | NCT02186301 | Non-Small Cell ... | Rociletinib Mon... Erlotinib Mono-... | 18 Years - | Clovis Oncology, Inc. | |
| SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma | NCT03874741 | Head and Neck S... | SCT200 | 18 Years - 75 Years | Sinocelltech Ltd. | |
| Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | NCT01526928 | Locally Advance... | Rociletinib Rociletinib Rociletinib Rociletinib Rociletinib Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors | NCT03692520 | Advanced Solid ... | SCT200 | 18 Years - 75 Years | Sinocelltech Ltd. | |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | NCT04664244 | Recurrent Cervi... Radiotherapy Epidermal Growt... Nimotuzumab Objective Respo... Progression-fre... Overall Surviva... | Combination of ... | 18 Years - | Peking Union Medical College Hospital | |
| A Study of DS-2248 in Participants With Advanced Solid Tumors | NCT01288430 | Solid Tumors Non-small Cell ... | DS-2248 | 18 Years - | Daiichi Sankyo | |
| Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | NCT03817567 | Esophageal Squa... | recombinant ant... | 18 Years - 75 Years | Sinocelltech Ltd. | |
| Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | NCT01833572 | Non-small-cell ... | Gefitinib | 18 Years - | Fudan University | |
| A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | NCT05940116 | Non-Small Cell ... Solid Tumor | HS-20117 | 18 Years - 75 Years | Hansoh BioMedical R&D Company | |
| Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | NCT01244191 | Non Squamous, N... | Tivantinib Placebo Erlotinib | 18 Years - | Daiichi Sankyo | |
| Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | NCT02861898 | Glioblastoma Brain Cancer Brain Neoplasm Brain Tumor Brain Neoplasm,... EGFR Gene Overe... GBM | Intra-arterial ... Intra-arterial ... | 18 Years - | Northwell Health | |
| HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | NCT04619004 | Non-Small Cell ... Non-Small Cell ... | Patritumab Deru... Patritumab Deru... | 18 Years - | Daiichi Sankyo | |
| Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer | NCT03521245 | HER2-positive B... | RNA sequencing Transcriptome a... Trastuzumab Chemotherapy | 18 Years - 80 Years | OmicsWay Corp. | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment | NCT01074333 | Colorectal Neop... | Cetuximab | - | Merck KGaA, Darmstadt, Germany | |
| Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00547157 | Cancer Head and Neck C... Oncology Squamous Cell C... | Panitumumab Cisplatin | 18 Years - | Amgen | |
| DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC | NCT00496652 | Cancer of the H... | Radiotherapy Zalutumumab | 18 Years - | Danish Head and Neck Cancer Group | |
| Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | NCT02147990 | Non-small Cell ... | Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | NCT03692689 | Triple Negative... | SCT200 | 18 Years - 75 Years | Sinocelltech Ltd. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Molecular Characterization of Cutaneous Tumors | NCT03092830 | Squamous Cell C... Basal Cell Carc... | Molecular testi... | 18 Years - | Rabin Medical Center | |
| Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer | NCT04755738 | Advanced Non Sm... | Almonertinib pl... | 18 Years - 80 Years | Qianfoshan Hospital | |
| Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC | NCT01775943 | Lung Neoplasms | - | Ulsan University Hospital | ||
| Blood Detection of EGFR Mutation For Iressa Treatment | NCT02282267 | Lung Adenocarci... | Gefitinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | NCT00739063 | Breast Cancer | Tarceva | - | M.D. Anderson Cancer Center | |
| Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR | NCT00240682 | Skin Diseases Carcinoma, Squa... | cetuximab | 18 Years - | Centre Hospitalier of Chartres | |
| A Study of DS-2248 in Participants With Advanced Solid Tumors | NCT01288430 | Solid Tumors Non-small Cell ... | DS-2248 | 18 Years - | Daiichi Sankyo | |
| Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer | NCT03692689 | Triple Negative... | SCT200 | 18 Years - 75 Years | Sinocelltech Ltd. | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | NCT03817567 | Esophageal Squa... | recombinant ant... | 18 Years - 75 Years | Sinocelltech Ltd. | |
| Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | NCT01833572 | Non-small-cell ... | Gefitinib | 18 Years - | Fudan University | |
| Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | NCT03817567 | Esophageal Squa... | recombinant ant... | 18 Years - 75 Years | Sinocelltech Ltd. | |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | NCT00225758 | Metastatic Brea... | Lapatinib | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer | NCT00927147 | Head and Neck C... | BNCT cetuximab | 18 Years - | Boneca Corporation | |
| HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer | NCT03260491 | Non-Small Cell ... | HER3-DXd (FL-DP... HER3-DXd (CTM-1... HER3-DXd (CTM-3... | 18 Years - | Daiichi Sankyo | |
| Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | NCT02147990 | Non-small Cell ... | Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| Blood Detection of EGFR Mutation For Iressa Treatment | NCT02282267 | Lung Adenocarci... | Gefitinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
